NM6603

DRUG2 trials

Sponsors

NucMito Pharmaceuticals Co. Ltd.

Conditions

Cancers

Phase 1

A Phase 1 Study of NM6603 in Advanced Solid Tumors

TerminatedNCT06046066

NucMito Pharmaceuticals Co. Ltd.Cancers

Start: 2023-08-31End: 2025-04-25Updated: 2026-05-07

Safety and Pharmacokinetics of NM6603 in Chinese Patients With Advanced Solid Tumors

RecruitingNCT07292038

NucMito Pharmaceuticals Co. Ltd.Cancers

Start: 2025-12-18End: 2026-11-30Target: 30Updated: 2026-01-14